Drug intelligence / Profile preview

C-Arriva

Development stage: Preclinical
Lead developer: Eye Pharma
Administration: Oral

Overview

C-Arriva is an oral nutraceutical formulation developed by EyePharma, combining high molecular weight hyaluronic acid (approximately 1,000,000 Da) with red orange (blood orange) extract. It is intended to support ocular and systemic well-being by addressing degenerative processes. The high molecular weight hyaluronic acid is designed to provide structural tissue support and hydration, while the red orange extract provides antioxidant effects to mitigate oxidative stress. The product is part of EyePharma's innovation pipeline for specialty eye care and general health maintenance.

Brand names: C-Arriva

Beyond the preview

Go deeper on C-Arriva.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-Arriva.

Explore the full profile